Welcome to our dedicated page for Veradigm SEC filings (Ticker: MDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Veradigm Inc. (MDRX) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures in a structured way. Veradigm describes itself as a healthcare technology company focused on healthcare data and technology solutions delivered through platforms, data, connectivity, and expertise, with activities organized around provider and payer & life science categories. Understanding how these activities are reflected in formal filings is an important part of evaluating the business.
Veradigm has publicly discussed its efforts to become current in its SEC financial reporting and has announced the filing of an Annual Report on Form 10-K for a prior fiscal year that includes restated financial statements. In that context, the company has referenced material weaknesses and internal control deficiencies and has outlined plans to remediate these issues while pursuing relisting of its common stock on a national stock exchange once reporting is current. These topics typically appear in sections of Form 10-K and related filings that address controls and procedures, risk factors, and management’s discussion and analysis.
On this page, users can access Veradigm’s key SEC documents as they become available, including annual reports on Form 10-K and quarterly reports on Form 10-Q, which provide detail on revenue by category (such as Provider and Payer & Life Science), cash and debt positions, and explanations of non-GAAP measures like adjusted EBITDA. Current Reports on Form 8-K can offer insight into events such as financing transactions, amendments to stockholder rights plans, and significant governance or reporting developments.
Stock Titan enhances these filings with AI-powered summaries that highlight important sections and explain complex accounting and disclosure topics in more accessible language. Users can also review ownership and transaction information reported on forms such as Form 4 when available, to better understand insider activity. Together, these tools make it easier to interpret Veradigm’s regulatory record and connect it to the company’s stated strategy in healthcare data and technology.
Veradigm Inc. (MDRX) has a new significant shareholder group led by Madison Avenue International LP. As of January 29, 2026, the group reports beneficial ownership of 7,167,999 shares of common stock, equal to about 6.6% of Veradigm’s outstanding shares.
The ownership percentage is calculated using 108,900,000 shares outstanding as of September 29, 2025, as cited from a prior company press release. The filing is made jointly by several related investment entities and Eli Samaha, who may be deemed to share voting and dispositive power. They certify the holdings are not for the purpose of changing or influencing control of Veradigm, other than activities solely in connection with a director nomination process.
Mason Capital Management LLC and its principals have disclosed a significant passive stake in Veradigm Inc. They report beneficial ownership of 6,283,161 shares of Veradigm common stock, representing 5.8% of the outstanding shares, as of an event dated 01/22/2026.
The ownership is held through Mason Capital Master Fund, L.P., over which Mason Capital Management has voting and investment discretion. Managing principals Kenneth M. Garschina and Michael E. Martino are reported as sharing voting and dispositive power over the same shares. The percentage is based on 108,900,000 Veradigm shares outstanding as of September 29, 2025.
The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Veradigm, consistent with a passive investment reported on Schedule 13G.
Veradigm Inc. reported that it has further amended its Stockholder Agreement with Charles Myers and Jessica Myers. Myers currently serves as an observer to Veradigm’s board of directors. On January 15, 2026, the company signed a Second Amendment that extends the agreement’s Termination Date to July 26, 2026, reflecting the value the company believes Myers has contributed in this observer role.
The amendment also allows Veradigm and the Myers Parties, by mutual consent, to extend the Termination Date again to January 26, 2027. This filing focuses on governance and board‑level engagement rather than financial results.
FAQ
What is the current stock price of Veradigm (MDRX)?
What is the market cap of Veradigm (MDRX)?
